CTRI/2010/091/000631已完成3 期
A randomized, active controlled, double blind, double dummy, parallel group, design, multi-centre, trial to compare, the efficacy and safety of 2.5 microgm and 5 microgm Tiotropium Inhalation Solution delivered by the Respimat® Inhaler with Tiotropium inhalation capsules 18 microgm delivered by the HandiHaler®
Boehringer Ingelheim Pharma GmbH Co KGBinger Strasse Ingelheim am RheinGermany15 个研究点 分布在 1 个国家目标入组 16,800 人开始时间: 2010年6月24日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 16,800
- 试验地点
- 15
- 主要终点
- 1. Time to death (all-cause mortality)
研究概览
简要总结
A randomized, active controlled, double blind, double dummy, parallel group, design, multi-centre, trial to compare, the efficacy and safety of 2.5 microgm and 5 microgm Tiotropium Inhalation Solution delivered by the Respimat® Inhaler with Tiotropium inhalation capsules 18 microgm delivered by the HandiHaler® in patients with Chronic Obstructive Pulmonary Disease (COPD). The primary outcome measures will be Time to death (all-cause mortality) and Time to first COPD exacerbation. The secondary outcomes will be Time to first major adverse cardiovascular event, Number of COPD exacerbations, Time to first hospitalisation due to COPD exacerbation and Number of hospitalisations due to COPD exacerbations. Target Sample size for India-500 subjects
研究设计
- 研究类型
- Interventional
- 分配方式
- Computer generated randomization
- 盲法
- Participant, Investigator and Outcome Assessor Blinded
入排标准
- 年龄范围
- 40.00 Year(s) 至 65.00 Year(s)（—）
- 性别
- All
入选标准
- •All patients must sign an informed consent consistent with International Conference on Harmonization Good Clinical Practice (ICH-GCP) guidelines prior to participation in the trial, which includes medication washout and restrictions.
- •Male or female patients 40 years of age or older.
- •Patients must be current or ex-smokers with a smoking history of 10 pack-years.
- •(Patients who have never smoked cigarettes must be excluded)
- •All patients must have a diagnosis of COPD (P06-12085), and must meet the following criteria: Relatively stable airway obstruction with a post-bronchodilator FEV1 less than 70% of predicted normal and post-bronchodilator FEV1 / FVC less than 70%.
排除标准
- •1.Significant diseases other than COPD.
- •A significant disease is defined as a disease or condition which, in the opinion of the investigator, may put the patient at risk because of participation in the study or may influence the patients ability to participate in the study.
- •2.Patients with a recent history (i.e., six months or less) of myocardial infarction.
- •3.Patients with any unstable or life-threatening cardiac arrhythmia requiring intervention or change in drug therapy during the last year.
- •4.Hospitalisation for cardiac failure (New York Heart Association (NYHA) Class III or IV) during the past year.
- •5.Known active tuberculosis.
- •6.Patients with a history of asthma, cystic fibrosis, bronchiectasis, interstitial lung disease, or pulmonary thromboembolic disease.
结局指标
主要结局
1. Time to death (all-cause mortality)
时间窗: 24 Months
次要结局
- 2. Number of COPD exacerbations(24 Months)
- 3. Time to first hospitalization due to COPD exacerbation(24 Months)
- 4. Number of hospitalizations due to COPD exacerbation(24 Months)
- 1. Time to first major adverse cardiovascular event(24 Months)
研究者
研究点 (15)
Loading locations...
相似试验
已完成
3 期
A Clinical study to evaluate Efficacy, Safety and Tolerability of 2% Rebamipide ophthalmic suspension Vs 0.1 % Sodium Hyaluronate Ophthalmic solution for treatment of patients with Dry EyeOther disorders of lacrimal gland,CTRI/2015/05/005783Ajanta Pharma Ltd200
已完成
3 期
Clinical Trial to Assess the Efficacy and Safety of YYD601 in the Treatment of Esophageal Reflux Disease (ERD)Erosive EsophagitisNCT03943992Yooyoung Pharmaceutical Co., Ltd.170
已完成
3 期
Clinical Trial to Evaluate the Efficacy and Safety of CKD-391HyperlipidemiaNCT02451098Chong Kun Dang Pharmaceutical385
已完成
3 期
Efficacy and safety ofR-TPR-024 / Lucentis® in patients with neovascular (wet) age-related macular degenerationneovascular (Wet) age related macular degenerationCTRI/2018/05/014065Reliance Life Sciences Pvt Ltd159
已完成
3 期
A Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Nepafenac Ophthalmic Suspension 0.3% w/v compared to Bromfenac Ophthalmic Solution 0.09% w/v in the treatment of Pain and Inflammation post Cataract Surgery.Disorders of the eye following cataract surgery, Pain and Inflammation in the Eye associated with Cataract Surgery,CTRI/2017/04/008299Ajanta Pharma Ltd278